Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
09 Nov 2020
Historique:
received: 07 10 2020
revised: 01 11 2020
accepted: 02 11 2020
entrez: 13 11 2020
pubmed: 14 11 2020
medline: 3 3 2021
Statut: epublish

Résumé

The glucagon-like peptide-1 receptor (GLP-1R) is an important regulator of blood glucose homeostasis. Ligand-specific differences in membrane trafficking of the GLP-1R influence its signalling properties and therapeutic potential in type 2 diabetes. Here, we have evaluated how different factors combine to control the post-endocytic trafficking of GLP-1R to recycling versus degradative pathways. Experiments were performed in primary islet cells, INS-1 832/3 clonal beta cells and HEK293 cells, using biorthogonal labelling of GLP-1R to determine its localisation and degradation after treatment with GLP-1, exendin-4 and several further GLP-1R agonist peptides. We also characterised the effect of a rare GLP1R coding variant, T149M, and the role of endosomal peptidase endothelin-converting enzyme-1 (ECE-1), in GLP1R trafficking. Our data reveal how treatment with GLP-1 versus exendin-4 is associated with preferential GLP-1R targeting towards a recycling pathway. GLP-1, but not exendin-4, is a substrate for ECE-1, and the resultant propensity to intra-endosomal degradation, in conjunction with differences in binding affinity, contributes to alterations in GLP-1R trafficking behaviours and degradation. The T149M GLP-1R variant shows reduced signalling and internalisation responses, which is likely to be due to disruption of the cytoplasmic region that couples to intracellular effectors. These observations provide insights into how ligand- and genotype-specific factors can influence GLP-1R trafficking.

Identifiants

pubmed: 33182425
pii: ijms21218404
doi: 10.3390/ijms21218404
pmc: PMC7664906
pii:
doi:

Substances chimiques

GLP1R protein, human 0
Glucagon-Like Peptide-1 Receptor 0
Ligands 0
Endothelin-Converting Enzymes EC 3.4.24.71

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Medical Research Council
ID : MR/S025618/1
Pays : United Kingdom
Organisme : EPSRC
ID : N/A
Organisme : H2020 European Research Council
ID : Starting Grant 715884
Organisme : Medical Research Council
ID : MR/N00275X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012646/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L02036X/1
Pays : United Kingdom
Organisme : FP7-HEALTH-2009-241592 EuroCHIP
ID : N/A
Organisme : Wellcome Trust
ID : 212625/Z/18/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106262/Z/14/Z, 106263/Z/14/Z
Pays : United Kingdom
Organisme : EU/EFPIA/Innovative Medicines Initiative 2 Joint Undertaking
ID : RHAPSODY grant No 11581
Organisme : Medical Research Council
ID : MR/R022259/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : N/A
Pays : United Kingdom
Organisme : Medical Research Council
ID : DIVA, MR/L02036X/1
Pays : United Kingdom
Organisme : NIHR Biomedical Research Centre
ID : N/A
Organisme : Medical Research Council
ID : MR/N00275X/1 and MR/S025618/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K001981/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12012/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/3
Pays : United Kingdom
Organisme : European Federation for the Study of Diabetes
ID : N/A
Organisme : Medical Research Council
ID : MR/N020472/1
Pays : United Kingdom
Organisme : British Society for Neuroendocrinology
ID : N/A
Organisme : Diabetes UK
ID : 17/0005681
Pays : United Kingdom
Organisme : Society for Endocrinology
ID : N/A
Organisme : Diabetes UK
ID : BDA/11/0004210, BDA/15/0005275, BDA 16/0005485
Pays : United Kingdom
Organisme : Medical Research Council
ID : MRC_MC_UU_12012/3
Pays : United Kingdom
Organisme : Diabetes UK
ID : Harry Keen Fellowship
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010676/1
Pays : United Kingdom
Organisme : Diabetes UK
ID : N/A
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K023667/1
Pays : United Kingdom
Organisme : NIHR
ID : N/A
Organisme : Academy of Medical Sciences
ID : N/A
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/N016947/1 and BB/S001565/1
Pays : United Kingdom

Références

Br J Pharmacol. 2015 Jan;172(2):704-19
pubmed: 24990314
Nat Chem Biol. 2014 Sep;10(9):700-6
pubmed: 25271346
Diabetes. 2014 Apr;63(4):1224-33
pubmed: 24296712
Regul Pept. 1995 Aug 22;58(3):149-56
pubmed: 8577927
Methods. 2017 Feb 15;115:28-41
pubmed: 28057586
Nat Rev Endocrinol. 2018 Jul;14(7):390-403
pubmed: 29728598
Diabetes. 2004 Dec;53 Suppl 3:S205-14
pubmed: 15561912
ACS Pharmacol Transl Sci. 2020 Mar 17;3(2):345-360
pubmed: 32296773
J Biol Chem. 1992 Apr 15;267(11):7402-5
pubmed: 1313797
Nat Commun. 2015 Dec 01;6:8918
pubmed: 26621478
Nature. 2018 Sep;561(7724):492-497
pubmed: 30209400
Biophys J. 2010 Jul 7;99(1):175-83
pubmed: 20655845
Endocrinology. 2003 Apr;144(4):1368-79
pubmed: 12639920
Cell. 2017 Nov 16;171(5):1165-1175.e13
pubmed: 29149605
Mol Metab. 2020 Jul;37:100991
pubmed: 32278079
Front Pharmacol. 2015 Apr 20;6:82
pubmed: 25941489
J Pharmacol Exp Ther. 2007 Jul;322(1):148-54
pubmed: 17395766
Nat Commun. 2017 Sep 5;8(1):443
pubmed: 28874659
Trends Pharmacol Sci. 2008 Aug;29(8):413-20
pubmed: 18606460
Nature. 2018 Mar 1;555(7694):121-125
pubmed: 29466332
Biophys J. 2000 Nov;79(5):2754-60
pubmed: 11053148
Biochem Pharmacol. 2018 May;151:59-68
pubmed: 29522713
J Pharmacol Exp Ther. 2015 Apr;353(1):52-63
pubmed: 25630467
Nat Commun. 2020 Jan 24;11(1):467
pubmed: 31980626
J Clin Invest. 2013 Oct;123(10):4182-94
pubmed: 24018562
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W382-8
pubmed: 15980494
Chem Sci. 2019 Sep 11;10(42):9872-9879
pubmed: 32015811
Mol Cell Endocrinol. 2014 Feb 15;382(2):938-49
pubmed: 24275181
J Biol Chem. 1990 May 25;265(15):8497-504
pubmed: 2160460
Diabetes. 2018 Mar;67(3):385-399
pubmed: 29284659
Sci Rep. 2016 May 19;6:26236
pubmed: 27196125
Biochem J. 2016 Sep 15;473(18):2881-91
pubmed: 27422784
ChemistryOpen. 2017 Jun 05;6(4):501-505
pubmed: 28794944
J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S36-9
pubmed: 11078330
Cell. 2018 Jan 11;172(1-2):41-54.e19
pubmed: 29249361
Pharmacol Rev. 2016 Oct;68(4):954-1013
pubmed: 27630114
ACS Chem Biol. 2016 Feb 19;11(2):400-8
pubmed: 26569370
Biotechnol Bioeng. 2014 Mar;111(3):504-17
pubmed: 24037521
Lancet. 2016 Feb 13;387(10019):679-90
pubmed: 26608256
Mol Pharmacol. 2018 Apr;93(4):266-269
pubmed: 29348268
Hum Mutat. 2012 Feb;33(2):359-63
pubmed: 22072597
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
Molecules. 2016 Dec 26;22(1):
pubmed: 28035964
J Biol Chem. 2018 May 11;293(19):7466-7473
pubmed: 29523687
Br J Pharmacol. 2018 Nov;175(21):4026-4035
pubmed: 28872669
Endocrinology. 2008 May;149(5):2200-7
pubmed: 18276747
Nat Commun. 2015 Jun 12;6:7324
pubmed: 26066081
Regul Pept. 2005 Aug 15;130(1-2):1-6
pubmed: 15975668
J Biol Chem. 2013 Sep 6;288(36):25689-700
pubmed: 23913690
Nature. 2020 Jul;583(7818):862-866
pubmed: 32555462
Biochem Pharmacol. 2015 Jan 1;93(1):72-84
pubmed: 25449603
Mol Metab. 2017 Oct;6(10):1173-1185
pubmed: 29031718
Jpn J Pharmacol. 2000 Sep;84(1):7-15
pubmed: 11043447
Curr Protoc Mol Biol. 2010 Oct;Chapter 14:Unit14.20
pubmed: 20890901
Front Neurosci. 2019 Oct 18;13:1112
pubmed: 31680842
Am J Physiol Endocrinol Metab. 2013 Jul 15;305(2):E161-70
pubmed: 23592482
Br J Pharmacol. 2020 May 20;:
pubmed: 32436216
J Mol Biol. 2019 May 17;431(11):2197-2212
pubmed: 30995449
Biochem J. 2019 Feb 8;476(3):513-533
pubmed: 30626614
Nat Metab. 2019 Jun;1(6):615-629
pubmed: 32694805
Diabetes Res Clin Pract. 2004 Oct;66(1):63-9
pubmed: 15364163
Nature. 2017 Jun 8;546(7657):248-253
pubmed: 28538729
Biochem J. 1995 Aug 15;310 ( Pt 1):203-14
pubmed: 7646446
Nat Commun. 2017 Jun 08;8:14836
pubmed: 28594001
Biochem Pharmacol. 2018 Oct;156:406-419
pubmed: 30195733
Nat Commun. 2018 Apr 23;9(1):1602
pubmed: 29686402
PLoS Biol. 2019 Aug 20;17(8):e3000097
pubmed: 31430273
Mol Pharmacol. 2011 Sep;80(3):486-97
pubmed: 21616920

Auteurs

Zijian Fang (Z)

Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK.
Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute and Department of Haematology, University of Cambridge, Cambridge CB2 0AW, UK.

Shiqian Chen (S)

Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK.

Yusman Manchanda (Y)

Section of Cell Biology and Functional Genomics, Imperial College London, London W12 0NN, UK.

Stavroula Bitsi (S)

Section of Cell Biology and Functional Genomics, Imperial College London, London W12 0NN, UK.

Philip Pickford (P)

Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK.

Alessia David (A)

Centre for Bioinformatics and System Biology, Department of Life Sciences, Imperial College London, London SW7 2BX, UK.

Maria M Shchepinova (MM)

Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, 80 Wood Lane, London W12 0BZ, UK.

Ivan R Corrêa (IR)

New England Biolabs, Ipswich, MA 01938, USA.

David J Hodson (DJ)

Institute of Metabolism and Systems Research (IMSR), and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham, Birmingham B15 2TT, UK.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham B15 2TT, UK.

Johannes Broichhagen (J)

Department of Chemical Biology, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, 13125 Berlin, Germany.
Department of Chemical Biology, Max Planck Institute for Medical Research, 69120 Heidelberg, Germany.

Edward W Tate (EW)

Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, 80 Wood Lane, London W12 0BZ, UK.

Frank Reimann (F)

Institute of Metabolic Science & MRC Metabolic Diseases Unit, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK.

Victoria Salem (V)

Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK.

Guy A Rutter (GA)

Section of Cell Biology and Functional Genomics, Imperial College London, London W12 0NN, UK.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 639798, Singapore.

Tricia Tan (T)

Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK.

Stephen R Bloom (SR)

Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK.

Alejandra Tomas (A)

Section of Cell Biology and Functional Genomics, Imperial College London, London W12 0NN, UK.

Ben Jones (B)

Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH